Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$32.7B
333M shares
52-week range
$64.80 – $119.10
55% from low
Sector
COMPUTER STORAGE DEVICES
Exchange
NYSE
CS
P/S (TTM)
7.7
EV / FCF (TTM)
255
Everpure Inc is a globalised technology company providing an integrated storage and data management platform. Data is foundational to customers' business transformation and increasingly central to their operational resilience and competitive differentiation. The company has evolved into a company that delivers a cloud experience with an intelligent, unified storage and data management platform (the Everpure Platform) that virtualizes data across on-premises, hybrid, and public cloud, and edge environments into a single storage layer with consistent control, built-in automation, and continuous modernization. Its business activities are a single operating and reportable segment. Operating in the USA and Rest of world, having maximum revenue in the USA.
www.purestorage.comNo one on the platform currently holds P.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 3,759,834 | $222.0M |
| Bridgewater Associatesas of 2025-12-31 | 110,266 | $7.4M |
No one on the platform has traded P yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 11.9% | — | — | — | ||
| Rev. Growth % | 15.6% | 16.8% | ||||
| Profit Margin % | 5.1% | 1.4% | -8.6% | |||
| Free Cash Flow Margin % | 16.8% | 17.3% | 9.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +4.2% on the P/E track.
At today's price, your expected annual return is +11.9% on the P/E track.
At today's price, your expected annual return is +18.6% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $5.1B | +38.9% | $2.78 | $2.62–$2.99 | 34.1× | 13 |
| 2028 | $6.2B | +22.4% | $3.55 | $2.85–$4.10 | 26.8× | 13 |
| 2029 | $7.2B | +16.0% | $4.47 | $3.69–$5.26 | 21.2× | 2 |
| 2030 | $6.8B | -5.7% | $3.91 | $3.44–$4.36 | 24.3× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-26 | $0.58 | $0.70 | +20.7% |
| 2026-05-27 | $0.40 | $0.47 | +18.2% |
| 2026-02-25 | $0.65 | $0.69 | +7.0% |
| 2025-12-02 | $0.58 | $0.58 | +0.0% |
| 2025-08-27 | $0.39 | $0.43 | +10.8% |
| 2025-05-28 | $0.25 | $0.29 | +18.0% |
| 2025-02-26 | $0.41 | $0.45 | +8.5% |
| 2024-12-03 | $0.42 |
| $0.50 |
| +19.0% |
| +0.10% |
| $19.7B |
| — |
| HPEHewlett Packard Enterprise Company | $55.41 | -10.76% | $73.4B | — |
| HPQHP Inc. | $34.02 | -4.11% | $31.1B | — |
Source: Financial Modeling Prep · peers by sector/industry
How is $P priced like winner-takes-all? $NTAP has some catching up to do
View on StockTwits ↗$P Inclusion on 21 Could touch that 92 low before Im a buyer on weakness
View on StockTwits ↗
$P If you played you got PAID $QQQ $SPY See our site since 2016 we have been doing this better than anyone
View on StockTwits ↗
What does the StockTwits community think of the new S&P additions? Of the four additions to the S&P 100, three are ranked Bearish. Of the ten additions to the S&P 600, only three are ranked Bullish. The middle rows are more positive with no Bearish scores. Of the three additions to the S&P 500, two are Bullish. Of the four additions to the S&P 400, two are Bullish. $SPY $DELL $PANW $BE $P
View on StockTwits ↗
@Twinter11 Very interesting study. They had improved PFS but, unfortunately, not OS. I guess that speaks to how poor their prognosis is in late line therapy. My AI analysis of this study relative to CLOVER: How Muthuraj et al. Validates the Underlying Biology: Confirms the Biomarker Mechanism: The study demonstrates that static baseline tissue biopsies miss responders because PD-L1 expression is dynamic and driven by myeloid/macrophage interactions in the bloodstream and tumor margins.Liquid Biopsy as a Trigger for "Pairing": Because patients whose circulating macrophage fusion cells turn high PD-L1 have a near-threefold improvement in PFS ($P = 0.0052$), tracking TMFC/CAML PD-L1 in peripheral blood provides a validated, non-invasive signal for when to add a checkpoint inhibitor. I guess one of the major hurdles will be getting the FDA to expand the labeling on checkpoint inhibitors to allow liquid biopsy results in lieu of tissue results. A BP will have to help tackle that.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.